Hohl Benjamin 4
4 · Enliven Therapeutics, Inc. · Filed Feb 17, 2026
Research Summary
AI-generated summary of this filing
Enliven Therapeutics (ELVN) CFO Benjamin Hohl Receives RSU Award
What Happened
Benjamin Hohl, Chief Financial Officer of Enliven Therapeutics (ELVN), received equity awards reported on Feb 12, 2026. The filing shows two grants: 25,000 shares (awarded at $0.00) and 150,000 derivative shares (awarded at $0.00), for a total of 175,000 restricted stock units (RSUs). These are compensatory grants (not open‑market purchases or sales) and do not represent immediate stock ownership until the RSUs vest.
Key Details
- Transaction date: February 12, 2026; Form 4 filed February 17, 2026 (appears timely given the federal holiday on Feb 16).
- Grants: 25,000 RSUs (direct award) and 150,000 derivative RSUs (reported as derivative award). Price: $0.00 per unit (standard for RSU compensation).
- Shares owned after transaction: Not specified in the portion of the filing provided.
- Vesting (per footnotes): 1/4 of the RSUs will vest on March 1, 2027, then 1/16th will vest each June 1, Sept 1, Dec 1 and March 1 thereafter, subject to continued service. (Footnote F2 confirms certain securities are RSUs; F3 in the filing references a separate option vesting schedule.)
- Filing timeliness: Filing date is within the required two business days given the Feb 16 holiday, so this appears timely.
Context
RSUs are a form of compensation that convert into shares only after vesting; they do not represent immediate cash proceeds or open‑market buying/selling. Grants like these are common for executive pay and reflect future incentive compensation rather than an immediate insider purchase or sale.
Insider Transaction Report
- Award
Common Stock
[F1][F2]2026-02-12+25,000→ 61,000 total - Award
Stock Option (right to buy)
[F3]2026-02-12+150,000→ 150,000 totalExercise: $27.16Exp: 2036-02-12→ Common Stock (150,000 underlying)
Footnotes (3)
- [F1]These securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. 1/4th of the RSUs will vest on March 1, 2027 and 1/16th of the RSUs will vest each June 1, September 1, December 1, and March 1 thereafter, subject to the Reporting Person continuing as a service provider through each such date.
- [F2]Certain of these securities are RSUs. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock, subject to the applicable vesting schedule and conditions of each RSU.
- [F3]1/4th of the shares subject to the option will vest on February 12, 2027 and 1/48th of the shares subject to the option will vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.